Literature DB >> 25221667

Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity.

Cynthia B Berry1, Michael Bubser2, Carrie K Jones2, John P Hayes3, James A Wepy3, Charles W Locuson4, J Scott Daniels4, Craig W Lindsley5, Corey R Hopkins5.   

Abstract

Herein, we report the structure-activity relationship of a chiral morpholine-based scaffold, which led to the identification of a potent and selective dopamine 4 (D4) receptor antagonist. The 4-chlorobenzyl moiety was identified, and the compound was designated an MLPCN probe molecule, ML398. ML398 is potent against the D4 receptor with IC50 = 130 nM and K i = 36 nM and shows no activity against the other dopamine receptors tested (>20 μM against D1, D2S, D2L, D3, and D5). Further in vivo studies showed that ML398 reversed cocaine-induced hyperlocomotion at 10 mg/kg.

Entities:  

Keywords:  Dopamine 4 receptor antagonist; ML398; MLPCN; addiction

Year:  2014        PMID: 25221667      PMCID: PMC4160761          DOI: 10.1021/ml500267c

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

Review 1.  Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.

Authors:  S Sanyal; H H Van Tol
Journal:  J Psychiatr Res       Date:  1997 Mar-Apr       Impact factor: 4.791

2.  Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine.

Authors:  M Rubinstein; T J Phillips; J R Bunzow; T L Falzone; G Dziewczapolski; G Zhang; Y Fang; J L Larson; J A McDougall; J A Chester; C Saez; T A Pugsley; O Gershanik; M J Low; D K Grandy
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

3.  L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  Philippe Huot; Tom H Johnston; James B Koprich; Ahmed Aman; Susan H Fox; Jonathan M Brotchie
Journal:  J Pharmacol Exp Ther       Date:  2012-05-22       Impact factor: 4.030

Review 4.  Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist.

Authors:  L J Bristow; M S Kramer; J Kulagowski; S Patel; C I Ragan; G R Seabrook
Journal:  Trends Pharmacol Sci       Date:  1997-06       Impact factor: 14.819

5.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

6.  Polymorphisms of the D4 dopamine receptor alleles in chronic alcoholism.

Authors:  S R George; R Cheng; T Nguyen; Y Israel; B F O'Dowd
Journal:  Biochem Biophys Res Commun       Date:  1993-10-15       Impact factor: 3.575

7.  Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice.

Authors:  M F O'Neill; G Shaw
Journal:  Psychopharmacology (Berl)       Date:  1999-08       Impact factor: 4.530

8.  Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects.

Authors:  M Kotler; H Cohen; R Segman; I Gritsenko; L Nemanov; B Lerer; I Kramer; M Zer-Zion; I Kletz; R P Ebstein
Journal:  Mol Psychiatry       Date:  1997-05       Impact factor: 15.992

Review 9.  Dopamine D4 receptors: beyond schizophrenia.

Authors:  Frank I Tarazi; Kehong Zhang; Ross J Baldessarini
Journal:  J Recept Signal Transduct Res       Date:  2004-08       Impact factor: 2.092

10.  Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  C Marin; E Aguilar; M C Rodríguez-Oroz; G D Bartoszyk; J A Obeso
Journal:  Psychopharmacology (Berl)       Date:  2009-01-22       Impact factor: 4.530

View more
  5 in total

1.  Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists.

Authors:  Jonathan O Witt; Andrea L McCollum; Miguel A Hurtado; Eric D Huseman; Daniel E Jeffries; Kayla J Temple; Hyekyung C Plumley; Anna L Blobaum; Craig W Lindsley; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2016-03-30       Impact factor: 2.823

2.  Homology modeling, molecular dynamic simulation, and docking based binding site analysis of human dopamine (D4) receptor.

Authors:  Minasadat Khoddami; Hamid Nadri; Alireza Moradi; Amirhossein Sakhteman
Journal:  J Mol Model       Date:  2015-02-04       Impact factor: 1.810

3.  Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists.

Authors:  Kirsten T Tolentino; Viktoriya Mashinson; Anish K Vadukoot; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2022-02-10       Impact factor: 2.823

4.  Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms.

Authors:  Hongzhao Wang; Zijian Qin; Aixia Yan
Journal:  Mol Divers       Date:  2021-02-03       Impact factor: 3.364

5.  Identification of Novel Dopamine D2 Receptor Ligands-A Combined In Silico/In Vitro Approach.

Authors:  Lukas Zell; Constanze Lainer; Jakub Kollár; Veronika Temml; Daniela Schuster
Journal:  Molecules       Date:  2022-07-11       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.